OBJECTIVE Patients with ANCA associated vasculitis (AAV) experience high levels of fatigue, despite disease remission. This study assessed the feasibility and acceptability of a definitive randomised controlled trial of a behavioural-based physical activity intervention to support fatigue self-management in AAV patients. METHODS AAV patients in disease remission with fatigue (Multidimensional Fatigue Inventory-20 general fatigue domain ≥) were randomly allocated to intervention or standard care in this single-centre open-label randomised controlled feasibility study. The intervention lasted 12 weeks and comprised eight face-to-face physical activity sessions with a facilitator and 12 weekly telephone calls. Participants were encour...
Background: Chronic fatigue is a poorly managed problem in people with inflammatory rheumatic diseas...
Objectives. To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make...
INTRODUCTION: Fatigue is one of the most frequent symptoms in anti-cancer immune therapy. Physical a...
OBJECTIVE: Patients with ANCA-associated vasculitis (AAV) experience high levels of fatigue, despite...
OBJECTIVE: Patients with ANCA-associated vasculitis (AAV) experience high levels of fatigue, despite...
OBJECTIVE: Patients with ANCA-associated vasculitis (AAV) experience high levels of fatigue, despite...
© 2018 Author(s) (or their employer(s)). Introduction Fatigue is a major cause of morbidity, limitin...
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See ...
Objectives. To identify the determinants of fatigue among patients with ANCA-associated vasculitis (...
OBJECTIVES: To identify the determinants of fatigue among patients with ANCA-associated vasculitis (...
Objectives: To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and m...
Objective: Chronic fatigue is a major burden of disease in patients with ANCA-Associated Vasculitis ...
Objectives. To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make...
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Background: Fatigue is a major sympt...
Background: Fatigue is a major symptom of RA and the need for effective interventions is evident. Pr...
Background: Chronic fatigue is a poorly managed problem in people with inflammatory rheumatic diseas...
Objectives. To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make...
INTRODUCTION: Fatigue is one of the most frequent symptoms in anti-cancer immune therapy. Physical a...
OBJECTIVE: Patients with ANCA-associated vasculitis (AAV) experience high levels of fatigue, despite...
OBJECTIVE: Patients with ANCA-associated vasculitis (AAV) experience high levels of fatigue, despite...
OBJECTIVE: Patients with ANCA-associated vasculitis (AAV) experience high levels of fatigue, despite...
© 2018 Author(s) (or their employer(s)). Introduction Fatigue is a major cause of morbidity, limitin...
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See ...
Objectives. To identify the determinants of fatigue among patients with ANCA-associated vasculitis (...
OBJECTIVES: To identify the determinants of fatigue among patients with ANCA-associated vasculitis (...
Objectives: To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and m...
Objective: Chronic fatigue is a major burden of disease in patients with ANCA-Associated Vasculitis ...
Objectives. To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make...
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Background: Fatigue is a major sympt...
Background: Fatigue is a major symptom of RA and the need for effective interventions is evident. Pr...
Background: Chronic fatigue is a poorly managed problem in people with inflammatory rheumatic diseas...
Objectives. To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make...
INTRODUCTION: Fatigue is one of the most frequent symptoms in anti-cancer immune therapy. Physical a...